UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 10, 2019

 

 AMPIO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in Charter)

  

Delaware

 

001-35182

 

26-0179592

(State or other jurisdiction of

incorporation or organization) 

 

(Commission

File No.) 

 

(IRS Employer

Identification No.) 

 

373 Inverness Parkway, Suite 200

Englewood, Colorado 80112

(Address of principal executive offices, including zip code)

 

(720) 437-6500

(Registrant’s telephone number, including area code)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:

    

Trading Symbol

    

Name of each exchange on which registered:

Common

 

AMPE

 

NYSE American

   

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ◻

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

 

 

 

Item 8.01 Other Events.  

 

On October 10, 2019, Ampio Pharmaceuticals, Inc. (the “Company”) issued a press release announcing an update on the AP-013 Phase III clinical trial and the Ampion manufacturing facility.  The AP-013 Phase III clinical trial is now enrolling patients at 23 of the 25 clinical sites authorized by the FDA and, as of October 8, 2019, 510 of the 1,034 patients to be enrolled had been injected and an additional 63 are currently in the screening. All required FDA CMC manufacturing pilot lots have been completed and documented and approximately 200,000 Ampion vials have been filled without contamination. Additionally, independent audit results of the manufacturing facility reflected no serious negative findings and concluded that the facility was ready for an FDA audit. A copy of the press release is provided as Exhibit 99.1 to this Current Report.

 

Item 9.01.  Financial Statements and Exhibits.

 

 

 

Exhibit Number

Description

 

 

99.1

Ampio Pharmaceuticals, Inc., press release dated October 10, 2019

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

AMPIO PHARMACEUTICALS, INC.

 

 

 

 

By: 

/s/ Michael Macaluso

 

 

Michael Macaluso

 

 

Chief Executive Officer

 

Dated: October 10, 2019

 

 

 

 

 

 

Exhibit 99.1

 

PICTURE 1

 

Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility

 

ENGLEWOOD, Colo., October 10,  2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a  development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled  “Evaluating the Efficacy and Safety of AmpionTM to treat Adults with Pain Due to Severe Osteoarthritis of the Knee”, today announced updates of the continued progress with their Phase III AP-013 clinical trial and their “state-of-the-Art” manufacturing facility. 

 

Progress Update on AP-013 Clinical Trial:
Ampio’s COO, Holli Cherevka, noted that  “Ampio is now enrolling patients at 23 of the 25 clinical sites authorized by the FDA and, as of October 8th, of the 1,034 patients to be enrolled in AP-013, 510 have been injected and an additional 63 are currently in the screening”.

“It is important to note,”   Ms. Cherevka continued,  “in the three randomized single-injection studies previously run by the Company, both reduction in pain and improvement in function were significantly greater for KL 4 patients treated with Ampion vs saline. These results imply that had there been increased patient enrollment, the p-values in each case would have demonstrated a statistically significant clinical benefit with the treatment utilizing Ampion compared to saline. The Company believes the FDA approved SPA trial design supporting the current AP-013 study addresses this issue by allowing > 1,000 KL 4 patients to be dosed.  In fact, the combined results of the prior single injection trials showed twice the necessary efficacy for both pain and function to be statistically significant in AP-013 (p-value < 0.05).”

Progress Update of Ampion Manufacturing facility:
Ampio’s CEO, Michael Macaluso,  acknowledged that it was unusual for a development stage biopharmaceutical company the size of Ampio to have constructed a GMP turnkey manufacturing facility capable of supplying global demand for its lead product, and further explained the rationale: “Since Dr. David Bar-Or was able to develop a process by which Ampion is extracted through utilization of a proprietary filtration process of the FDA Licensed blood product, Human Serum Albumin (HSA),  and the Company was confident of the efficacy of the drug,  we determined it would be prudent to build a compact (~3300 sq.ft.), highly efficient and cost-effective, GMP manufacturing facility in our corporate headquarters. Importantly,  we believe this will enable the Company to have direct oversite and control over the ongoing manufacturing and commercial launch of  Ampion shortly after FDA approval of Ampion.  Furthermore, our facility utilizes sterile, single-use processing disposables in an automated, proprietary process that creates what we believe is a market advantage with flexible pricing, strong operating margins and the capacity to meet global demand. My confidence that our manufacturing facility will meet both short and long term demand, should Ampion receive FDA approval, is supported by the following:

·

All the required FDA CMC manufacturing pilot lots have been completed and documented. 

·

Approximately 200,000 Ampion vials have been filled without contamination.

·

The “ball room” platform technology used in the facility is flexible and supports possible expansion of indications by providing filling of IV bags and syringes as well as vials.

·

Based on observed production rates, the three-shift annual capacity of this facility would be  ~ 8,000,000 vials at very low direct product cost and strong operating margins. 

·

The Company engaged RMC Pharma (http://www.rmcpharma.com/) an independent third-party regulatory consulting firm to conduct a comprehensive audit over multiple days while the Company was conducting CMC manufacturing runs. The audit results reflected no serious negative findings and RMC concluded in their opinion the facility is ready for FDA audit.

·

The Company has secured long term HSA supply agreements.”

 

 

 

 

 

 

 

PICTURE 2

 

About Special Protocol Assessment (SPA)
A  SPA is a process in which sponsors may ask to meet with the FDA to reach agreement on the design and size of certain clinical trials to determine if they adequately address scientific and regulatory requirements for a study that could support marketing approval. Our SPA agreement for the above referenced study indicates concurrence by the FDA with the adequacy and acceptability of specific critical elements of overall protocol design for the study, which we intend to support a future Biologic License Application (BLA).

About Osteoarthritis
Osteoarthritis (OA) is an incurable and progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments, and bone. Certain risk factors in conjunction with natural wear and tear lead to the breakdown of cartilage. OA is caused by inflammation of the soft tissue and bony structures of the joint, which worsens over time and leads to progressive thinning of articular cartilage. Other symptoms include narrowing of the joint space, synovial membrane thickening, osteophyte formation and increased density of subchondral bone.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio’s lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2032 and may be eligible for 12-year FDA market exclusivity if approved as a novel biologic under the biologics price competition and innovation act (BPCIA).

Forward-Looking Statements
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” “would have” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to Ampion™ and its classification, as well as those associated with pending regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
Dan Stokely, CFO
Phone: (720) 437-6500
info@ampiopharma.com